Intrexon | XON - Cost Of Sales


Intrexon reported $1.01M in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Amgen USD 1.6B 187M Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
AstraZeneca USD -204M 3.48B Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Incyte USD 104.5M 16.68M Mar/2026
Intrexon USD 1.01M 344K Jun/2024
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Ligand Pharmaceuticals USD 11.37M 8.38M Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
MannKind USD 39.58M 5.94M Mar/2026
Merck USD 2.94B 380M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Thermo Fisher Scientific USD 6.96B 620M Mar/2026
Veracyte USD 38.49M 794K Mar/2026
Xencor USD 61.66M 50.95M Jun/2025